Coherus Announces Final Overall Survival Results Of JUPITER-02 Phase 3 Trial Evaluating Toripalimab In Nasopharyngeal Carcinoma
Portfolio Pulse from Benzinga Newsdesk
Coherus announced final overall survival results of the JUPITER-02 Phase 3 trial evaluating toripalimab in nasopharyngeal carcinoma. The trial showed a statistically significant improvement in overall survival for patients treated with toripalimab combined with chemotherapy, compared to chemotherapy alone.

June 05, 2023 | 9:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Coherus announced positive results from the JUPITER-02 Phase 3 trial of toripalimab in nasopharyngeal carcinoma, which may lead to increased investor interest and potential stock price growth.
The positive results from the JUPITER-02 Phase 3 trial indicate that toripalimab has potential in treating nasopharyngeal carcinoma. This may lead to increased investor interest in Coherus, as the company's product shows promise in a new therapeutic area. As a result, the stock price may experience growth in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100